FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083354965> ?p ?o ?g. }

• W3083354965 endingPage "528" @default.
• W3083354965 startingPage "528" @default.
• W3083354965 abstract "Abstract Interruption of EGFR signaling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumors. EGFR tyrosine kinase inhibitors (TKIs) provide a favorable treatment outcome in EGFR mutation positive NSCLC patients. However, many patients eventually develop progressive disease after treatment. Such acquired resistance limits the long-term efficacy of these EGFR TKIs in the clinic. The mechanisms of acquired resistance include a variety of mutations of the EGFR and crosstalk with the adjacent cMet receptors that allow the tumor to partially compensate the EGFR activity. EMB-01 is an innovative bispecific antibody developed based on EpimAb's proprietary FIT-Ig® platform to target EGFR and cMET on tumor cells simultaneously. The anti-EGFR and anti-cMet Fab-domains in each EMB-01 arm are fused directly in-tandem in a unique crisscross orientation without any mutations or use of peptide linkers to form a final tetravalent binding complex with the corresponding receptors on cell surface. We have demonstrated that EMB-01 can maintain all the biological activity from parental monoclonal antibody (mAb) to block ligand binding and the downstream signal pathway. In addition, such tetravalent binding feature is found to induce significant co-degradation of EGFR and cMET in various tumor cells, and such effect is unattainable by either mAb alone or in combination, demonstrating a unique synergistic function of EMB-01. At equivalent doses, EMB-01 induces significantly stronger anti-tumor activity in PDX and CDX tumor models than that of anti-EGFR mAb or anti-cMet mAb alone. Furthermore, EMB-01 shows significant anti-tumor activity in anti-EGFR mAb resistant tumor model. These results demonstrate the potential benefit of EMB-01 in treating EGFR and/or cMET driven cancers, particularly in cases where patients develop acquired resistance due to secondary EGFR mutations in the kinase domain or cMET activation. Currently, EMB-01 has initiated a Phase I/II clinical trial with advanced/metastatic solid tumors. Citation Format: Fang Ren, Xuan Wu, Dandan Yang, Danqing Wu, Shiyong Gong, Yingxi Zhang, Stephan Lensky, Chengbin Wu. EMB-01: An innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 528." @default.
• W3083354965 created "2020-09-11" @default.
• W3083354965 creator A5007598146 @default.
• W3083354965 creator A5009096841 @default.
• W3083354965 creator A5014484697 @default.
• W3083354965 creator A5019601191 @default.
• W3083354965 creator A5037949442 @default.
• W3083354965 creator A5057714513 @default.
• W3083354965 creator A5062642936 @default.
• W3083354965 creator A5076307381 @default.
• W3083354965 date "2020-08-15" @default.
• W3083354965 modified "2023-10-15" @default.
• W3083354965 title "Abstract 528: EMB-01: An innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy" @default.
• W3083354965 doi "https://doi.org/10.1158/1538-7445.am2020-528" @default.
• W3083354965 hasPublicationYear "2020" @default.
• W3083354965 type Work @default.
• W3083354965 sameAs 3083354965 @default.
• W3083354965 citedByCount "6" @default.
• W3083354965 countsByYear W30833549652021 @default.
• W3083354965 countsByYear W30833549652022 @default.
• W3083354965 countsByYear W30833549652023 @default.
• W3083354965 crossrefType "journal-article" @default.
• W3083354965 hasAuthorship W3083354965A5007598146 @default.
• W3083354965 hasAuthorship W3083354965A5009096841 @default.
• W3083354965 hasAuthorship W3083354965A5014484697 @default.
• W3083354965 hasAuthorship W3083354965A5019601191 @default.
• W3083354965 hasAuthorship W3083354965A5037949442 @default.
• W3083354965 hasAuthorship W3083354965A5057714513 @default.
• W3083354965 hasAuthorship W3083354965A5062642936 @default.
• W3083354965 hasAuthorship W3083354965A5076307381 @default.
• W3083354965 hasConcept C101544691 @default.
• W3083354965 hasConcept C116227048 @default.
• W3083354965 hasConcept C126322002 @default.
• W3083354965 hasConcept C159654299 @default.
• W3083354965 hasConcept C161879069 @default.
• W3083354965 hasConcept C170493617 @default.
• W3083354965 hasConcept C185592680 @default.
• W3083354965 hasConcept C203014093 @default.
• W3083354965 hasConcept C2779438470 @default.
• W3083354965 hasConcept C42362537 @default.
• W3083354965 hasConcept C502942594 @default.
• W3083354965 hasConcept C542903549 @default.
• W3083354965 hasConcept C71924100 @default.
• W3083354965 hasConceptScore W3083354965C101544691 @default.
• W3083354965 hasConceptScore W3083354965C116227048 @default.
• W3083354965 hasConceptScore W3083354965C126322002 @default.
• W3083354965 hasConceptScore W3083354965C159654299 @default.
• W3083354965 hasConceptScore W3083354965C161879069 @default.
• W3083354965 hasConceptScore W3083354965C170493617 @default.
• W3083354965 hasConceptScore W3083354965C185592680 @default.
• W3083354965 hasConceptScore W3083354965C203014093 @default.
• W3083354965 hasConceptScore W3083354965C2779438470 @default.
• W3083354965 hasConceptScore W3083354965C42362537 @default.
• W3083354965 hasConceptScore W3083354965C502942594 @default.
• W3083354965 hasConceptScore W3083354965C542903549 @default.
• W3083354965 hasConceptScore W3083354965C71924100 @default.
• W3083354965 hasIssue "16_Supplement" @default.
• W3083354965 hasLocation W30833549651 @default.
• W3083354965 hasOpenAccess W3083354965 @default.
• W3083354965 hasPrimaryLocation W30833549651 @default.
• W3083354965 hasRelatedWork W178368023 @default.
• W3083354965 hasRelatedWork W2027911638 @default.
• W3083354965 hasRelatedWork W2029323837 @default.
• W3083354965 hasRelatedWork W2105383945 @default.
• W3083354965 hasRelatedWork W2150814991 @default.
• W3083354965 hasRelatedWork W2160930114 @default.
• W3083354965 hasRelatedWork W2320148073 @default.
• W3083354965 hasRelatedWork W2321063763 @default.
• W3083354965 hasRelatedWork W284991352 @default.
• W3083354965 hasRelatedWork W4283519445 @default.
• W3083354965 hasVolume "80" @default.
• W3083354965 isParatext "false" @default.
• W3083354965 isRetracted "false" @default.
• W3083354965 magId "3083354965" @default.
• W3083354965 workType "article" @default.